New hope for transplant patients: could a simple infusion stop a dangerous virus?

NCT ID NCT06958796

First seen Nov 03, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tests whether giving an extra medicine (CMV immunoglobulin) after standard antiviral treatment can prevent late CMV infection in high-risk kidney and liver transplant recipients. About 80 adults who are at high risk because their donor had CMV but they did not will receive either the medicine or a placebo. The goal is to see if this approach reduces the number of serious CMV infections and related complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT; COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.